News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pluristem Therapeutics (PSTI) Granted Patent In Russia For Treatment Of Inflammatory Bowel Disease Using Placenta-Derived Cells


6/19/2014 8:45:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HAIFA, Israel, June 19, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that Russia's Federal Service for Intellectual Property has granted to Pluristem Patent No. 2515156 titled, "Methods of Treating Inflammatory Colon Diseases". The patent covers methods for treating ulcerative colitis or Crohn's disease using placenta-derived cells. This patent has already been issued to Pluristem in South Africa and is currently pending in several other jurisdictions.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES